Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with <i>ALK</i>‐positive non‐small‐cell lung cancer: Case report and review of the literature

Wiest, Nathaniel E.; Tzou, Katherine S.; Olson, Matthew T.; Herchko, Steven; Bajalia, Essa M.; Thiel, David D.; Lou, Yanyan; Zhao, Yujie; Manochakian, Rami

doi:10.1002/ccr3.4278

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, crizotinib is a dual c-MET and ALK inhibitor [ 10 , 15 – 17 ], but accumulating number of case reports demonstrated that crizotinib is associated with development of cystic lesions in the kidneys, liver, and pancreas [ 20 , 24 , 28 – 35 ]. While the mechanism of CARC formation remains to be defined, as proposed by Wiest et al [ 30 ], complete collection of the following information from the advanced NSCLC patients treated with crizotinib is recommended, that is, patient’s general information including age, gender, race/ethnicity, history of renal cysts; clinical information of primary including stage at diagnosis, genetic information, treatment history, treatment response, PFS; tyrosine kinase inhibitor-associated renal cysts including time to diagnosis, laterality, pathology, symptoms, complications, abnormalities in vitals and labs.…”

Section: Discussionmentioning

confidence: 99%

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature

Zhang,

Xu,

et al. 2024

Diagn Pathol

View full text Add to dashboard Cite

Background Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with positive rearrangement of anaplastic lymphoma kinase (ALK). However, an increased incidence of renal and hepatic cysts has been reported in the patients on crizotinib treatment. Case presentation Here, we describe a case of a 71-year-old Chinese women developed multiple cystic lesions in kidney and liver during crizotinib treatment for the primary and metastatic NSCLC. The renal and hepatic cysts were noted by CT scan 3 months after crizotinib treatment, which were spontaneously and significantly regressed after stopping crizotinib. Conclusions Based on literature review and our experience in this case report, we concluded that crizotinib-associated renal cyst (CARCs) has features of malignancy and abscess in radiographic imaging, and thus, pathological confirmation is necessary to avoid inappropriate treatment decision. In addition, to benefit the patients with progress-free survival (PFS), switching from crizotinib to alectinib is recommended for the treatment of NSCLC patients who developed CARCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature

Zhang,

Xu,

et al. 2024

Diagn Pathol

View full text Add to dashboard Cite

show abstract

“…One interesting finding is that prolonged PFS was observed in ALK -fusion NSCLC patients receiving crizotinib with associated renal cystic formation. 32,33 A patient we recently reported from our institution experienced spontaneous regression of crizotinib related renal cysts, after having a total of 19 months of crizotinib treatment with partial response (PR). 32 Four of 10 cases including Wiest NE 33 ,s data report a prolonged median PFS of around 23 months in crizotinib related renal cysts for ALK -rearranged NSCLC patients.…”

Section: First-generation Alk Inhibitor Crizotinibmentioning

confidence: 99%

Renal cyst formation complicating ALK inhibitors

Niu

Wakelee²,

Anand

2023

Journal of Onco-Nephrology

View full text Add to dashboard Cite

With rapid discovery of oncogenic deriver genes over the past decade, several tyrosine kinase inhibitors (TKIs) were developed to target the anaplastic lymphoma kinase (ALK) aberration in non-small cell lung cancers (NSCLCs), including first, second and third-generation ALK inhibitors for ALK-rearranged NSCLC treatment. However with recent data published from several clinical trials and retrospective studies investigating the efficacy of these TKIs in ALK-rearranged NSCLC patients, development of renal cysts is a side effect associated with first generation TKI crizotinib; the mechanism for cyst formation, and whether it is a class effect, is unclear. In this review we will summarize published data on development of kidney injury and renal cysts associated with ALK inhibitors with focus on crizotinib-related renal cysts.

show abstract

Crizotinib

2021

Reactions Weekly

View full text Add to dashboard Cite

Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK‐positive non‐small‐cell lung cancer: Case report and review of the literature

Cited by 3 publications

References 21 publications

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature

Renal cyst formation complicating ALK inhibitors

Crizotinib

Contact Info

Product

Resources

About